Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | GFER | P55789 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9380274 | 0.93 | KMT2A (0.87) | ALDH1A1KMT2AALOX15ALOX12L3MBTL1 | |
| SCHEMBL10780921 | 0.88 | ALDH1A1 (0.77) | ALDH1A1KMT2AALOX15ALOX12L3MBTL1 | |
| SCHEMBL19780825 | 0.87 | ALDH1A1 (0.77) | ALDH1A1KMT2AALOX15ALOX12L3MBTL1 | |
| SCHEMBL19782763 | 0.85 | ALDH1A1 (0.74) | ALDH1A1KMT2AALOX15ALOX12L3MBTL1 | |
| SCHEMBL809441 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KMT2AALOX15ALOX12L3MBTL1 | |
| SCHEMBL20357747 | 0.79 | ALDH1A1 (0.66) | ALDH1A1KMT2AALOX15ALOX12L3MBTL1 | |
| SCHEMBL19780860 | 0.79 | MAPT (0.65) | ALDH1A1KMT2AALOX15ALOX12L3MBTL1 | |
| SCHEMBL19781258 | 0.78 | MAPT (0.63) | ALDH1A1KMT2AALOX15ALOX12L3MBTL1 | |
| SCHEMBL8739251 | 0.78 | EZH2 (0.76) | ALDH1A1KMT2AALOX15ALOX12L3MBTL1 | |
| SCHEMBL9372093 | 0.76 | KMT2A (0.61) | ALDH1A1KMT2AALOX15ALOX12L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | GEORGETOWN UNIVERSITY (US) | 2026-03-26 | — | — | US | disclosed |
| EP-3484983-B1 | SYNERGISTIC LUBRICATING OIL COMPOSITION CONTAINING MIXTURE OF ANTIOXIDANTS | CHEVRON ORONITE CO (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20180016512-A1 | Synergistic Lubricating Oil Composition Containing Mixture of Antioxidants | CHEVRON ORONITE COMPANY LLC | 2018-01-18 | — | — | US | disclosed |
| WO-2018013181-A1 | SYNERGISTIC LUBRICATING OIL COMPOSITION CONTAINING MIXTURE OF ANTIOXIDANTS | CHEVRON ORONITE COMPANY LLC (US) | 2018-01-18 | — | — | WO | disclosed |
| US-9504729-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504729-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-02-04 | — | — | US | disclosed |
| US-9186365-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-17 | — | — | US | disclosed |
| US-9186365-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-17 | — | — | US | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| WO-2011014825-A2 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | ALDH1A1 1615/4885KMT2A 3811/4885ALOX15 3009/4885 |
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | PAX3, FOXO1, PAXBP1 | ALDH1A1 2739/4885KMT2A 545/4885ALOX15 4788/4885 |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | ALDH1A1 1615/4885KMT2A 3811/4885ALOX15 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.